NCT07527715 Cardiac Magnetic Resonance-Clinical Prediction Model-Dilated Cardiomyopathy
| NCT ID | NCT07527715 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shandong Provincial Hospital |
| Condition | Cardiomyopathy, Dilated |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2021-12-01 |
| Primary Completion | 2028-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2021-12-01 with a primary completion date of 2028-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Dilated cardiomyopathy (DCM) is a common and serious heart disease characterized by left ventricular enlargement and impaired pumping function, with adverse prognosis (including heart failure, arrhythmia, heart-related hospitalization, and death) being a major concern for patients. Currently, a critical gap exists in accurately predicting which DCM patients are at high risk of these severe outcomes, limiting targeted clinical care. This observational, non-invasive study aims to develop and validate a clinical prediction model for early risk warning of adverse prognosis in DCM patients. The model integrates multi-parameter stress perfusion cardiac magnetic resonance (MP stress perfusion CMR)-a safe, high-resolution imaging technique that assesses cardiac structure, function, blood perfusion, and tissue damage under mild stress-and standard clinical data (e.g., age, gender, blood pressure, and routine heart test results). The model will be trained and tested using follow-up data from hundreds of DCM patients, with the analysis identifying patterns in CMR and clinical data associated with adverse outcomes. Once validated for accuracy, the model will provide doctors with personalized risk scores to prioritize care for high-risk patients (e.g., early intervention, close monitoring) and avoid over-treatment for lower-risk individuals. Beyond clinical application, the study will enhance understanding of DCM progression, laying the groundwork for improved diagnostic tools, more effective treatments, and better strategies to prevent DCM-related complications, ultimately improving patient quality of life and reducing mortality.
Eligibility Criteria
Inclusion Criteria 1.An elevated left ventricular end-diastolic volume indexed to body surface area and reduced LVEF, compared with published age- and gender-specific reference values Exclusion Criteria 1. significant coronary artery disease (CAD), defined as a stenosis of ˃50% in a major coronary artery 2. infiltrative disease 3. valvular cardiomyopathy 4. arrhythmogenic cardiomyopathy 5. congenital heart disease
Contact & Investigator
Xi-ming Wang
STUDY CHAIR
Shandong Provincial Hospital
Frequently Asked Questions
Who can join the NCT07527715 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cardiomyopathy, Dilated. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07527715 currently recruiting?
Yes, NCT07527715 is actively recruiting participants. Contact the research team at wwx990511@163.com for enrollment information.
Where is the NCT07527715 trial being conducted?
This trial is being conducted at Jinan, China.
Who is sponsoring the NCT07527715 clinical trial?
NCT07527715 is sponsored by Shandong Provincial Hospital. The principal investigator is Xi-ming Wang at Shandong Provincial Hospital. The trial plans to enroll 2,000 participants.